Recent data indicated the enormous potential of JNK inhibitors in NB treatment, as they have been reported to induce NB cell death via direct activation of p53-, JNK-, Bcl-2-, and caspase-dependent pathways [29,30]. Here, BCL2 is linked to neuroblastoma.